Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESTROSTEP 21 vs CARISOPRODOL AND ASPIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females >= 15 years of age who have achieved menarche, are not pregnant, and desire oral contraception
Relief of discomfort associated with acute painful musculoskeletal conditions
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Ethinyl estradiol is metabolized primarily via CYP3A4 and undergoes glucuronidation and sulfation. Norethindrone acetate is deacetylated to norethindrone, which is metabolized by CYP3A4 and other CYP enzymes, and undergoes reduction and glucuronidation.
Carisoprodol is N-deacetylated via CYP2C19 to meprobamate, a schedule IV controlled substance. Aspirin is hydrolyzed to salicylic acid in the liver and gastrointestinal tract.
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 95-97% bound to albumin and SHBG.
Carisoprodol: ~60% bound to albumin. Aspirin: 80-90% bound to albumin (salicylate); highly protein-bound at therapeutic concentrations.
Ethinyl estradiol: 2.5-4.5 L/kg; norethindrone: 3.5-5.5 L/kg. Indicates extensive tissue distribution.
Carisoprodol: ~0.7 L/kg (large Vd, extensive tissue distribution). Aspirin: ~0.15 L/kg (salicylate; low Vd, primarily in extracellular fluid). Clinical meaning: Carisoprodol distributes into CNS and muscle; aspirin remains largely in plasma and interstitial space.
Ethinyl estradiol: 38-48% (oral, first-pass metabolism); norethindrone acetate: 50-70% (oral, deacetylation to norethindrone).
Oral: Carisoprodol: ~90% (well absorbed). Aspirin: ~40-50% (presystemic hydrolysis in GI mucosa and liver; rectal: 100% absorbed, but avoids first-pass).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
e GFR 30-59 m L/min: avoid or reduce dose; e GFR <30 m L/min: contraindicated.
Contraindicated in acute hepatitis, severe cirrhosis, benign or malignant liver tumors, or Child-Pugh class C cirrhosis. Use with caution in Child-Pugh class A or B; consider alternative therapy.
Child-Pugh Class A: caution; Class B or C: contraindicated.
Not indicated for use before menarche. Post-menarche: same dosing as adults; use lowest effective dose for shortest duration.
Not recommended for pediatric patients under 12 years of age. For older adolescents, weight-based dosing of aspirin 10-15 mg/kg/dose every 4-6 hours (max 80 mg/kg/day) and carisoprodol 5-10 mg/kg/dose three times daily; avoid routine use due to risk of Reye's syndrome.
Not indicated for postmenopausal women; no established dosing in elderly. Consider alternative therapies as necessary.
Initiate at lowest effective dose; monitor for CNS depression, renal function, and bleeding risk. Avoid in patients with significant renal impairment or peptic ulcer disease.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women > 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
None.
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), especially in smokers and women over 35,Hepatic neoplasia (benign and malignant) reported,Hypertension and gallbladder disease,Carbohydrate and lipid effects; monitor in diabetic patients,Ocular lesions (e.g., retinal thrombosis); discontinue if unexplained vision loss or proptosis occurs,Hereditary angioedema exacerbation,Chloasma; avoid sun exposure,Menstrual irregularities (e.g., breakthrough bleeding, amenorrhea),Depression; discontinue if severe
Dependence and withdrawal: Carisoprodol may cause dependence and withdrawal symptoms.,Sedation and CNS depression: Additive effects with alcohol and other CNS depressants.,Reye's syndrome: Aspirin use in children and teenagers with viral illness.,Gastrointestinal bleeding: Aspirin increases risk of GI bleeding.,Hypersensitivity reactions: Anaphylaxis, angioedema.
Thrombophlebitis, thromboembolic disorders, or history thereof (e.g., deep vein thrombosis, pulmonary embolism),Cerebrovascular disease (e.g., stroke, TIA),Coronary artery disease (e.g., myocardial infarction, angina),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Benign or malignant liver tumors,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35 years of age
Hypersensitivity to carisoprodol or aspirin.,Children and teenagers with viral infections (Reye's syndrome risk).,Active peptic ulcer disease or GI bleeding.,Severe hepatic impairment.,History of asthma induced by aspirin or NSAIDs.,Concomitant use with meprobamate-containing products.
No specific food interactions. Grapefruit juice may increase estrogen exposure (mild effect). Maintain consistent timing with meals to reduce nausea if needed. Avoid alcohol if liver function is compromised.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid high-tyramine foods (e.g., aged cheese, cured meats) as aspirin may potentiate tyramine effects.
Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and neural tube defects. Second and third trimesters: associated with fetal genital abnormalities, feminization of male fetuses, and potential long-term reproductive effects. Use in early pregnancy for emergency contraception is not recommended due to potential risks.
First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk of premature closure of ductus arteriosus and oligohydramnios; carisoprodol not well studied but may cause neonatal withdrawal. Avoid in third trimester due to aspirin's antiprostaglandin effects.
Estrostep 21 is excreted in breast milk in small amounts; ethinyl estradiol M/P ratio approximately 0.1; norethindrone M/P ratio ~0.5. May reduce milk production and quality, especially in early lactation. Use generally avoided during breastfeeding; consider progestin-only alternatives.
Aspirin and carisoprodol are excreted into breast milk. M/P ratio for aspirin is approximately 0.6-0.9; carisoprodol M/P ratio not established. Risk of Reye syndrome with aspirin, neonatal salicylate accumulation, and sedation from carisoprodol. Use not recommended during breastfeeding.
Estrostep 21 is contraindicated in pregnancy; no dose adjustments recommended as use is avoided. Pharmacokinetic changes during pregnancy (increased hepatic metabolism, volume of distribution) would require dose adjustment if used, but due to risks, alternative therapy is indicated.
Pregnancy increases clearance of aspirin and carisoprodol; however, avoid use due to fetal risks. No recommended dose adjustments; contraindicated, especially in third trimester.
ESTROSTEP 21 is a monophasic oral contraceptive containing norethindrone acetate and ethinyl estradiol. Due to its low estrogen dose (20 mcg), it may be associated with more breakthrough bleeding compared to higher-dose pills. It is indicated for contraception and may be used for acne treatment. The 21-day regimen requires a 7-day hormone-free interval. Counsel patients that smoking increases the risk of serious cardiovascular adverse effects; avoid in women over 35 who smoke.
Carisoprodol is metabolized to meprobamate, a controlled substance; monitor for abuse potential. Aspirin increases bleeding risk; avoid in children with viral illness due to Reye's syndrome. Combination may cause CNS depression and impaired motor function. Use with caution in renal impairment.
Take one tablet daily at the same time each day for 21 days, then no pills for 7 days.,If you miss a dose, follow the package instructions; use backup contraception if missed more than one tablet.,Do not smoke while taking this medication; smoking increases risk of blood clots, stroke, and heart attack, especially if over 35.,Common side effects include spotting, nausea, breast tenderness, and headache; these often improve after a few cycles.,Seek emergency care if you have signs of a blood clot: sudden leg pain, chest pain, shortness of breath, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Take missed pills as soon as remembered; do not take more than two tablets in one day.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Take with food or milk to reduce stomach upset.,Do not use in children or teenagers with flu-like symptoms or chickenpox due to risk of Reye's syndrome.,Report signs of bleeding (easy bruising, black stools, vomiting blood) or allergic reactions (rash, swelling, difficulty breathing).,Rapid discontinuation may cause withdrawal symptoms (anxiety, insomnia, muscle twitching).
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESTROSTEP 21 vs CARISOPRODOL AND ASPIRIN, answered by our medical review team.
ESTROSTEP 21 is a Combined Oral Contraceptive that works by Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.. CARISOPRODOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESTROSTEP 21 and CARISOPRODOL AND ASPIRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESTROSTEP 21 is: One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. The standard adult dose of CARISOPRODOL AND ASPIRIN is: 1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESTROSTEP 21 and CARISOPRODOL AND ASPIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESTROSTEP 21 is classified as Category C. Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and. CARISOPRODOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.